Cover Image
Market Research Report

Malignant Mesothelioma Global Clinical Trials Review, H2, 2019

Published by GlobalData Product code 146469
Published Content info 383 Pages
Delivery time: 1-2 business days
Price
Back to Top
Malignant Mesothelioma Global Clinical Trials Review, H2, 2019
Published: December 18, 2019 Content info: 383 Pages
Description

GlobalData's clinical trial report, "Malignant Mesothelioma Global Clinical Trials Review, H2, 2019" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Product Code: GDHC5211CTIDB

Table of Contents

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 22
  • Clinical Trials by Phase in E7 Countries 24
  • Clinical Trials in E7 Countries by Trial Status 25
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 27
  • Clinical Trials by Trial Status 28
  • Clinical Trials by End Point Status 30
  • Subjects Recruited Over a Period of Time 31
  • Clinical Trials by Sponsor Type 32
  • Prominent Sponsors 33
  • Top Companies Participating in Malignant Mesothelioma Therapeutics Clinical Trials 35
  • Prominent Drugs 37
  • Latest Clinical Trials News on Malignant Mesothelioma 38
  • Nov 07, 2019: MaxCyte to present at BIO-Europe 2019 38
  • Oct 24, 2019: MaxCyte advances phase I clinical trial of lead CARMA mRNA-based Cell Therapy to third cohort of patients 38
  • Sep 30, 2019: MaxCyte Presents Updates on First-in-class CARMA Platform at Upcoming Meetings 38
  • Sep 30, 2019: Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy 39
  • Clinical Trial Profile Snapshots 41

Appendix 395

  • Abbreviations 395
  • Definitions 395
  • Research Methodology 396
  • Secondary Research 396
  • About GlobalData 397
  • Contact Us 397
  • Disclaimer 397
  • Source 398

List of Tables

  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2019* 8
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
  • Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
  • Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
  • Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
  • Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2019* 18
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2019* 23
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2019* 26
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
  • Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 32
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

List of Figures

  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
  • Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
  • Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
  • Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
  • Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2019* 17
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2019* 22
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
  • Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 32
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37
  • GlobalData Methodology 396
Back to Top